DE3582356D1 - Kovalent modifizierte bakterielle polysaccharide, stabile kovalente konjugate von diesen polysacchariden und immunogenischen proteinen mit zweiwertigen bruecken und verfahren zur herstellung von solchen polysacchariden und konjugaten und zur befestigung der kovalenz. - Google Patents

Kovalent modifizierte bakterielle polysaccharide, stabile kovalente konjugate von diesen polysacchariden und immunogenischen proteinen mit zweiwertigen bruecken und verfahren zur herstellung von solchen polysacchariden und konjugaten und zur befestigung der kovalenz.

Info

Publication number
DE3582356D1
DE3582356D1 DE8585400872T DE3582356T DE3582356D1 DE 3582356 D1 DE3582356 D1 DE 3582356D1 DE 8585400872 T DE8585400872 T DE 8585400872T DE 3582356 T DE3582356 T DE 3582356T DE 3582356 D1 DE3582356 D1 DE 3582356D1
Authority
DE
Germany
Prior art keywords
polysaccharides
methods
conjugals
bridges
covalently modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8585400872T
Other languages
English (en)
Inventor
Stephen Marburg
Peter J Kniskern
Richard L Tolman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of DE3582356D1 publication Critical patent/DE3582356D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
DE8585400872T 1984-05-10 1985-05-06 Kovalent modifizierte bakterielle polysaccharide, stabile kovalente konjugate von diesen polysacchariden und immunogenischen proteinen mit zweiwertigen bruecken und verfahren zur herstellung von solchen polysacchariden und konjugaten und zur befestigung der kovalenz. Expired - Lifetime DE3582356D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60873884A 1984-05-10 1984-05-10

Publications (1)

Publication Number Publication Date
DE3582356D1 true DE3582356D1 (de) 1991-05-08

Family

ID=24437774

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8585400872T Expired - Lifetime DE3582356D1 (de) 1984-05-10 1985-05-06 Kovalent modifizierte bakterielle polysaccharide, stabile kovalente konjugate von diesen polysacchariden und immunogenischen proteinen mit zweiwertigen bruecken und verfahren zur herstellung von solchen polysacchariden und konjugaten und zur befestigung der kovalenz.

Country Status (19)

Country Link
US (1) US4695624A (de)
EP (1) EP0161188B1 (de)
JP (1) JPH0825899B2 (de)
KR (1) KR910002553B1 (de)
CN (1) CN1020733C (de)
AT (1) ATE62255T1 (de)
AU (1) AU589559B2 (de)
CA (1) CA1259450A (de)
CY (2) CY1765A (de)
DE (1) DE3582356D1 (de)
DK (2) DK171420B1 (de)
ES (1) ES8700298A1 (de)
GR (1) GR851120B (de)
HK (1) HK18894A (de)
IE (1) IE58088B1 (de)
IL (1) IL75064A (de)
NZ (1) NZ211953A (de)
PT (1) PT80413B (de)
ZA (1) ZA853505B (de)

Families Citing this family (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8304304A (nl) * 1983-12-14 1985-07-01 Landbouw Hogeschool Werkwijze voor het winnen van een gelvormend polysaccharide, het gewonnen gelvormende polysaccharide, het met behulp van een dergelijk polysaccharide gewonnen gel alsmede werkwijze ter bereiding van synthetische oligo- en polysacchariden.
US4882317A (en) * 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4837003A (en) * 1984-09-13 1989-06-06 Mallinckrodt, Inc. Radiolabeled antibody fragments
US4659839A (en) * 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US4851521A (en) * 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
US5202431A (en) * 1985-07-08 1993-04-13 Fidia, S.P.A. Partial esters of hyaluronic acid
US5283323A (en) * 1985-08-07 1994-02-01 The United States Of America As Represented By The Department Of Health And Human Services Method of producing immune response
DE3601136A1 (de) * 1986-01-16 1987-07-23 Max Planck Gesellschaft Hemmstoffe der reversen transkriptase fuer prophylaxe und therapie von retrovirus-infektionen in saeugetieren
CA1331355C (en) * 1986-04-21 1994-08-09 Bioenterprises Pty. Ltd Immunopotentation
US5374426A (en) * 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
AU598426B2 (en) * 1986-11-06 1990-06-21 University Of British Columbia, The Anhydrous enhanced coupling of proteins
US5976839A (en) * 1987-03-13 1999-11-02 Bioenterprises Pty Limited Immunopotentiation through covalent linkage between immunogen and immunopotentiating molecules
US5002883A (en) * 1987-10-30 1991-03-26 Abbott Laboratories Covalent attachment of antibodies and antigens to solid phases using extended length heterobifunctional coupling agents
US4994385A (en) * 1987-10-30 1991-02-19 Abbott Laboratories Heterobifunctional coupling agents
US5785973A (en) * 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
US5204098A (en) * 1988-02-16 1993-04-20 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-protein conjugates
US5010176A (en) * 1988-11-10 1991-04-23 Eli Lilly And Company Antibody-drug conjugates
US7118757B1 (en) * 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
US4963534A (en) * 1989-05-19 1990-10-16 Merck & Co., Inc. Process for solubilizing polyanoinic bacterial polysaccharides in aprotic solvents
US5039610A (en) * 1989-06-12 1991-08-13 Merck & Co., Inc. Process for removing bacterial endotoxin from gram-negative polysaccharides
US5019502A (en) * 1989-06-12 1991-05-28 Merck & Company, Inc. Process for removing bacterial endotoxin from gram-negative polysaccharides
US5045456A (en) * 1989-06-12 1991-09-03 Merck & Co., Inc. Process for removing bacterial endotoxin from gram-negative polysaccharides
JPH04506662A (ja) * 1989-07-14 1992-11-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
CA2064194A1 (en) * 1989-07-27 1991-01-28 Nelson Teng Lipid a analog/immunogenic carrier conjugates and the use thereof as vaccines
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
CA2071478A1 (en) * 1989-10-27 1991-04-28 Jeffery A. Bluestone Methods and compositions for promoting immunopotentiation
IT1237764B (it) * 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
RO111416B1 (ro) * 1989-12-14 1996-10-31 Ca Nat Research Council Polizaharide modificate de neisseria meningitidis si e coli, combinatii antigenice si metoda de imunizare
CA2047031A1 (en) * 1990-07-19 1992-01-20 Stephen Marburg Peptide-polysaccharide-protein conjugate vaccines
IL98845A0 (en) * 1990-07-19 1992-07-15 Merck & Co Inc Coconjugate vaccines comprising immunogenic protein,hiv related peptides,and anionic moieties,their preparation and pharmaceutical compositions containing them
IL99077A0 (en) * 1990-08-13 1992-07-15 Merck & Co Inc New embodiments of the hiv principal neutralizing determinant and pharmaceutical compositions containing them
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
WO1992008790A1 (en) * 1990-11-14 1992-05-29 Cargill, Incorporated Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
EP0630260B1 (de) * 1991-03-12 2001-01-24 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Konjugate bestehend aus polysaccharid und protein
WO1992020316A2 (en) * 1991-05-14 1992-11-26 University Of Connecticut Targeted delivery of genes encoding immunogenic proteins
CA2070961C (en) * 1991-06-14 2004-12-07 Michael Chorev Thiol-reactive maleimido-based radiolabeling reagents
US5370872A (en) * 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
US5314811A (en) * 1992-07-13 1994-05-24 Merck & Co., Inc. Process for converting lipid-containing bacterial capsular polysaccharide into lipid-free polysaccharide
US5371197A (en) * 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
IT1262896B (it) * 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US5463028A (en) 1992-04-03 1995-10-31 The Trustees Of Columbia University In The City Of New York Reagents for generating a polyclonal hydrolytic antibody response against cocaine and the monoclonal hydrolytic antibodies against cocaine derived through these reagents
CA2132342A1 (en) * 1992-04-06 1993-10-14 Kenneth F. Buechler Novel opiate derivatives and protein and polypeptide opiate derivative conjugates and labels
US5470997A (en) * 1992-04-06 1995-11-28 Biosite Diagnostics Incorporated Amphetamine derivatives and protein and polypeptide amphetamine derivative conjugates and labels
US5331109A (en) * 1992-04-06 1994-07-19 Biosite Diagnostics Incorporated Phencyclidine derivatives and protein and polypeptide phencyclidine derivative conjugates and labels
US5314822A (en) * 1992-10-15 1994-05-24 Merck & Co., Inc. Method of clonal growth of Streptococcus pneumoniae
US5274122A (en) * 1992-10-15 1993-12-28 Merck & Co., Inc. Acidic derivatives of homocysteine thiolactone
US6037455A (en) * 1992-11-09 2000-03-14 Biosite Diagnostics Incorporated Propoxyphene derivatives and protein and polypeptide propoxyphene derivative conjugates and labels
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US20030108548A1 (en) * 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
US5866132A (en) * 1995-06-07 1999-02-02 Alberta Research Council Immunogenic oligosaccharide compositions
US5780606A (en) * 1995-06-07 1998-07-14 Connaught Laboratories Limited Neisseria meningitidis capsular polysaccharide conjugates
US5695768A (en) * 1995-06-07 1997-12-09 Alberta Research Council Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
CN1146444C (zh) 1995-06-23 2004-04-21 史密斯克莱·比奇曼生物公司 含有吸附于磷酸铝上的多糖偶联抗原的疫苗组合物
US6410025B1 (en) 1996-02-14 2002-06-25 Merck & Co., Inc. Polysaccharide precipitation process
WO1997030171A1 (en) * 1996-02-14 1997-08-21 Merck & Co., Inc. Polysaccharide precipitation process
US6309646B1 (en) 1996-05-09 2001-10-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates
US6267961B1 (en) 1996-11-22 2001-07-31 Baxter International Inc. Direct methods for molar-mass determination of fragments of Haemophilus influenzae type b capsular polysaccharides and vaccine preparation
CA2246760C (en) * 1997-01-21 2012-01-10 Pasteur Merieux Serums & Vaccins Polysaccharide-peptide-conjugates
ATE278418T1 (de) * 1997-04-24 2004-10-15 Jackson H M Found Military Med Kopplung unmodifizierter proteinen an haloacyl- oder dihaloacyl-derivatisierten polysacchariden zur herstellung von protein-polysaccharide impfstoffen
US20040087020A1 (en) * 1997-05-28 2004-05-06 Chiron S.P.A. Culture medium with yeast or soy bean extract as amino acid source and no protein complexes of animal origin
EP1849860B1 (de) * 1997-05-28 2010-11-17 Novartis Vaccines and Diagnostics S.r.l. Verfahren zur Herstellung eines immunogenen Faktors von Corynebacterium diphtheriae unter Verwendung eines Kulturmediums mit Hefeextrakt als Aminosäurenquelle und ohne Proteinkomplexe tierischer Herkunft
BR9811475A (pt) * 1997-07-17 2000-08-15 North American Vaccine Inc Conjugados imunogênicos compreendendo uma porina meningocóccica de grupo b e um polissacarìdeo de h. influenzae
US6224880B1 (en) 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
EP1027061B1 (de) * 1997-10-03 2005-05-25 Galenica Pharmaceuticals, Inc. Iminbildende polysaccharide, deren herstellung und verwendung als zusatzmittel und immunstimulierende mittel
US6756361B1 (en) * 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
AU760669B2 (en) 1998-04-28 2003-05-22 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
US20030224011A1 (en) * 2001-05-29 2003-12-04 Conley Anthony J Hepatitis c virus conjugates
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
DE60230670D1 (de) * 2001-12-11 2009-02-12 Merck & Co Inc Staphylococcus aureus exopolysaccharid und verfahren
JP2006500963A (ja) 2002-08-02 2006-01-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン組成物
AU2003274511B2 (en) 2002-10-11 2009-06-04 Glaxosmithkline Biologicals S.A. Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
WO2004039417A2 (en) 2002-11-01 2004-05-13 Glaxosmithkline Biologicals S.A. Drying process
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004067030A2 (en) 2003-01-30 2004-08-12 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
EP1603590A4 (de) * 2003-03-07 2008-08-27 Merck & Co Inc Influenza-virus-vakzine
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
ES2397923T3 (es) 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos
WO2005032584A2 (en) 2003-10-02 2005-04-14 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination
US20050169941A1 (en) * 2004-01-29 2005-08-04 Andrew Lees Use of amino-oxy functional groups in the preparation of protein-polysaccharide conjugate vaccines
EP1737899B1 (de) 2004-04-20 2015-07-08 Dendritic Nanotechnologies, Inc. Dendritische polymere mit verbesserter amplifikation und innerer funktion
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
DK1740217T3 (da) 2004-04-30 2011-09-26 Novartis Ag Meningokok-konjugat-vaccination
EP1755667B1 (de) 2004-06-01 2013-07-17 Merck Sharp & Dohme Corp. Stabiles peptidmimetikum des hiv gp41-fusionszwischenproduktes
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
MX2007010402A (es) 2005-04-20 2008-01-22 Dendritic Nanotechnologies Inc Polimeros dendriticos con amplificacion mejorada y funcionalidad interior.
MX2007016403A (es) 2005-06-27 2008-03-07 Glaxosmithkline Biolog Sa Composicion inmunogenica.
CA2614640A1 (en) * 2005-07-11 2007-01-18 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
BRPI0613625A2 (pt) * 2005-07-19 2011-01-18 Dow Global Technologies Inc vacinas da gripe recombinantes
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
AR058592A1 (es) 2005-12-22 2008-02-13 Glaxosmithkline Biolog Sa Vacuna
CN101024669B (zh) * 2006-02-17 2013-03-13 福州昌晖生物工程有限公司 一种可溶性的多糖-蛋白交联抗原的制备方法
NZ572054A (en) 2006-03-22 2011-12-22 Novartis Ag Regimens for immunisation with meningococcal conjugates
SG177907A1 (en) * 2006-06-14 2012-02-28 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
US7491517B2 (en) * 2006-07-19 2009-02-17 Jeeri R Reddy Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135
PL2097102T3 (pl) 2006-09-07 2012-10-31 Glaxosmithkline Biologicals Sa Szczepionka skojarzona o zmniejszonej ilości antygenu wirusa polio
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
TW200914042A (en) 2007-05-02 2009-04-01 Glaxosmithkline Biolog Sa Vaccine
CN101883583B (zh) 2007-06-26 2017-05-17 葛兰素史密丝克莱恩生物有限公司 含有肺炎链球菌荚膜多糖缀合物的疫苗
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CA2716212A1 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
CA2777837C (en) 2008-10-27 2017-07-11 Novartis Ag Purification method
JP5830009B2 (ja) 2009-04-14 2015-12-09 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対して免疫化するための組成物
US20120135037A1 (en) 2009-06-01 2012-05-31 Mizel Steven B Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
WO2011017101A2 (en) 2009-07-27 2011-02-10 Fina Biosolutions, Llc Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
JP2013502918A (ja) 2009-08-27 2013-01-31 ノバルティス アーゲー 髄膜炎菌ｆＨＢＰ配列を含むハイブリッドポリペプチド
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
US20130022639A1 (en) 2009-09-30 2013-01-24 Novartis Ag Expression of meningococcal fhbp polypeptides
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
EP2493499A1 (de) 2009-10-27 2012-09-05 Novartis AG Modifizierte meningokokken-fhbp-polypeptide
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
CA2836140C (en) 2009-12-17 2016-06-21 Fina Biosolutions, Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
US9173954B2 (en) 2009-12-30 2015-11-03 Glaxosmithkline Biologicals Sa Polysaccharide immunogens conjugated to E. coli carrier proteins
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
JP2013521770A (ja) 2010-03-10 2013-06-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン組成物
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
AU2010351576B2 (en) 2010-04-23 2014-08-14 FinaBioSolutions, LLC Simple method for simultaneous removal of multiple impurities from culture supernatants to ultralow levels
ES2744471T3 (es) 2010-09-04 2020-02-25 Glaxosmithkline Biologicals Sa Ensayos de anticuerpos bactericidas para evaluar la inmunogenia y la potencia de vacunas de sacárido capsular meningocócico
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
EP2638058B1 (de) 2010-11-12 2017-01-11 Merck Sharp & Dohme Corp. Enolase-peptid-konjugat-impfstoffe gegen staphylococcus aureus
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
GB201106225D0 (en) 2011-04-13 2011-05-25 Glaxosmithkline Biolog Sa Fermentation process
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
MX354924B (es) 2011-11-07 2018-03-22 Novartis Ag Molecula portadora que comprende un antigeno spr0096 y un spr2021.
SI3106176T1 (en) 2011-12-06 2018-04-30 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
JP2015510872A (ja) 2012-03-07 2015-04-13 ノバルティス アーゲー Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2885625A1 (en) 2012-10-02 2014-04-10 Glaxosmithkline Biologicals S.A. Nonlinear saccharide conjugates
KR20150065878A (ko) 2012-10-12 2015-06-15 글락소스미스클라인 바이오로지칼즈 에스.에이. 조합 백신에서 사용하기 위한 가교되지 않은 무세포 백일해 항원
SI2925355T1 (en) 2012-11-30 2018-04-30 Glaxosmithkline Biologicals S.A. Antigens and combinations of Pseudomonas antigens
ES2750525T3 (es) 2012-12-27 2020-03-26 Glaxosmithkline Biologicals Sa Procedimientos y composiciones relacionados con CRM197
US9827190B2 (en) 2013-02-01 2017-11-28 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists
ES2597832T3 (es) 2013-03-08 2017-01-23 Janssen Vaccines & Prevention B.V. Vacuna acelular contra la tosferina
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
ES2930318T3 (es) 2014-02-14 2022-12-09 Pfizer Conjugados glucoproteicos inmunogénicos
SG11201606478YA (en) 2014-02-28 2016-09-29 Glaxosmithkline Biolog Sa Modified meningococcal fhbp polypeptides
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3034516A1 (de) 2014-12-19 2016-06-22 Novartis AG Reinigung von Streptokokkenkapselpolysaccharid
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
EP3269385A1 (de) 2016-07-12 2018-01-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumokokken-polysaccharid-proteinkonjugatzusammensetzung
EP3474890A1 (de) 2016-06-22 2019-05-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften E. V. Pneumokokken-polysaccharid-proteinkonjugat-zusammensetzung
MX2019002489A (es) 2016-09-02 2019-10-21 Sanofi Pasteur Inc Vacuna contra neisseria meningitidis.
US11027005B2 (en) 2016-10-20 2021-06-08 Km Biologics Co., Ltd. Method for producing Hib conjugate vaccine using PRP with lowered molecular weight
US20210108002A1 (en) 2016-12-06 2021-04-15 Glaxosmithkline Biologicals Sa Purification Process For Capsular Polysaccharide
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
WO2020016322A1 (en) 2018-07-19 2020-01-23 Glaxosmithkline Biologicals Sa Processes for preparing dried polysaccharides
EP3607967A1 (de) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modifizierte meningokokken fhbp polypeptide
EP3894431A2 (de) 2018-12-12 2021-10-20 GlaxoSmithKline Biologicals SA Modifizierte trägerproteine zur o-verknüpften glykosylierung
US20220118072A1 (en) 2019-02-11 2022-04-21 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3757217A1 (de) 2019-06-27 2020-12-30 GlaxoSmithKline Biologicals S.A. Verfahren zur proteinaufreinigung
EP3777884A1 (de) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogene zusammensetzung
CN115605222A (zh) 2019-09-27 2023-01-13 辉瑞公司（Us） 脑膜炎奈瑟氏菌组合物及其方法
EP3799884A1 (de) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogene zusammensetzungen
EP3900739A1 (de) 2020-04-21 2021-10-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetische streptococcus-pneumoniae-saccharid-konjugate zum konservierten membranprotein
EP3919076A1 (de) 2020-06-02 2021-12-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetische oligosaccharidimpfstoffe gegen streptococcus pneumoniae mit mikropartikel-adjuvans-formulierungen
JP2023529925A (ja) 2020-06-12 2023-07-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ナノ粒子ワクチンを使用する細菌免疫化
BR112022023234A2 (pt) 2020-06-25 2023-01-03 Glaxosmithkline Biologicals Sa Proteínas de exotoxina a modificada
GB202013262D0 (en) 2020-08-25 2020-10-07 Glaxosmithkline Biologicals Sa Vaccine Composition
US20240000958A1 (en) 2020-11-13 2024-01-04 Glaxosmithkline Biologicals Sa Novel carriers and conjugation methods
TW202245836A (zh) 2021-02-19 2022-12-01 美商賽諾菲巴斯德公司 重組ｂ型腦膜炎球菌疫苗
WO2023111826A1 (en) 2021-12-14 2023-06-22 Glaxosmithkline Biologicals Sa Bacterial immunization using qbeta hairpin nanoparticle constructs
WO2023200704A1 (en) 2022-04-11 2023-10-19 Sanofi Pasteur Inc. Protein-saccharide conjugation with sodium cyanoborohydride
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2024030931A1 (en) 2022-08-03 2024-02-08 Sanofi Pasteur Inc. Adjuvanted immunogenic composition against neisseria meningitidis b
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4003792A (en) * 1967-07-01 1977-01-18 Miles Laboratories, Inc. Conjugates of acid polysaccharides and complex organic substances
US3856471A (en) * 1968-08-05 1974-12-24 Nasa Amino acid analysis
GB1316990A (en) * 1970-09-17 1973-05-16 Roche Products Ltd Imidazolyl derivatives
US4185090A (en) * 1972-02-02 1980-01-22 Abbott Laboratories Chemically modified endotoxin immunizing agent
CA1023287A (en) * 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
SE431758B (sv) * 1977-03-04 1984-02-27 Pharmacia Fine Chemicals Ab Som tioleringsreagens eller berarmatris for enzymer anvendbart derivat av en sh-grupphaltig polymer
DE2862449D1 (en) * 1977-08-22 1984-11-22 Nat Res Dev Macromolecular covalent conjugates, methods for preparing and pharmaceutical compositions containing them
US4286964A (en) * 1979-10-12 1981-09-01 Seed Brian S Polyfunctional epoxides and halohydrins used as bridging groups to bind aromatic amine group-containing alcohols and thiols to hydroxyl bearing substrates
US4415665A (en) * 1980-12-12 1983-11-15 Pharmacia Fine Chemicals Ab Method of covalently binding biologically active organic substances to polymeric substances
US4379843A (en) * 1981-01-26 1983-04-12 Peter Cashion Immobilization of polynucleotides and polypeptides with tritylated polysaccharides
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4451446A (en) * 1982-03-04 1984-05-29 Smithkline-Rit Process for the preparation of polysaccharide-protein complexes from bacterial capsules, obtained products and immunogenic compositions containing them
JPS58167519A (ja) * 1982-03-30 1983-10-03 Teijin Ltd 細胞毒性複合体及びその製造法
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
IE940698L (en) * 1984-04-05 1985-10-05 Univ Missouri Vaccine and serum for endotoxin associated disease and method of preparing same as well as to methods of immunization and treatment of such disease and to a detoxified endotoxin and bacterial mutant
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates

Also Published As

Publication number Publication date
AU4221485A (en) 1985-11-14
IL75064A (en) 1988-11-30
PT80413B (en) 1987-04-16
IL75064A0 (en) 1985-09-29
DK205585D0 (da) 1985-05-09
DK171420B1 (da) 1996-10-21
JPS60248622A (ja) 1985-12-09
DK205585A (da) 1985-11-11
ATE62255T1 (de) 1991-04-15
EP0161188A2 (de) 1985-11-13
GR851120B (de) 1985-11-25
DK171137B1 (da) 1996-06-24
CA1259450A (en) 1989-09-12
PT80413A (en) 1985-06-01
CY98041I2 (en) 2010-07-28
DK98595A (da) 1995-09-07
EP0161188B1 (de) 1991-04-03
KR850007982A (ko) 1985-12-11
CN1020733C (zh) 1993-05-19
EP0161188A3 (en) 1987-07-22
ZA853505B (en) 1985-12-24
US4695624A (en) 1987-09-22
IE851134L (en) 1985-11-10
JPH0825899B2 (ja) 1996-03-13
ES542919A0 (es) 1986-10-16
ES8700298A1 (es) 1986-10-16
KR910002553B1 (ko) 1991-04-24
CN85104164A (zh) 1987-02-04
IE58088B1 (en) 1993-06-30
CY1765A (en) 1994-07-15
AU589559B2 (en) 1989-10-19
HK18894A (en) 1994-03-11
NZ211953A (en) 1990-01-29

Similar Documents

Publication Publication Date Title
DE3582356D1 (de) Kovalent modifizierte bakterielle polysaccharide, stabile kovalente konjugate von diesen polysacchariden und immunogenischen proteinen mit zweiwertigen bruecken und verfahren zur herstellung von solchen polysacchariden und konjugaten und zur befestigung der kovalenz.
ATE78492T1 (de) Kovalentlich modifizierte neutrale bakterielle polysaccharide, stabile kovalente konjugate zwischen diesen polysacchariden und immunogenischen proteinen und verfahren zur herstellung dieser polysaccharide und konjugate.
FI981807A (fi) Menetelmä terapeuttisesti käyttökelpoisten starburst-konjugaattien valmistamiseksi
NZ221065A (en) Conjugates of antibodies and toxins with sulphur-containing linking groups
DE59008706D1 (de) Einschmelzglas zur Herstellung von Glas-Metall-Dichtungen.
EP0320942A3 (de) Polysaccharide und makromolekulare Verbindungen davon
SE8403929L (sv) Rekombinant-dna-molekyl, transformerade mikroorganismer och forfarande for framstellning av penicillin v-amidas
SG14094G (en) Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition